Gastrointestinal tract (GIT) involvement is a common cause of debilitating symptoms in patients with systemic sclerosis (SSc). There are no disease modifying therapies for this condition and the treatment remains symptomatic, largely owing to the lack of a clear understanding of its pathogenesis.
SUMMARY Background
Gastrointestinal tract (GIT) involvement is a common cause of debilitating symptoms in patients with systemic sclerosis (SSc). There are no disease modifying therapies for this condition and the treatment remains symptomatic, largely owing to the lack of a clear understanding of its pathogenesis.
Aims
To investigate novel aspects of the pathogenesis of gastrointestinal involvement in SSc. To summarise existing knowledge regarding the cardinal clinical gastrointestinal manifestations of SSc and its pathogenesis, emphasising recent investigations that may be valuable in identifying potentially novel therapeutic targets.
Methods
Electronic (PubMed/Medline) and manual Google search.
Results
The GIT is the most common internal organ involved in SSc. Any part of the GIT from the mouth to the anus can be affected. There is substantial variability in clinical manifestations and disease course and symptoms are nonspecific and overlapping for a particular anatomical site. Gastrointestinal involvement can occur in the absence of cutaneous disease. Up to 8% of SSc patients develop severe GIT symptoms. This subset of patients display increased mortality with only 15% survival at 9 years. Dysmotiity of the GIT causes the majority of symptoms. Recent investigations have identified a novel mechanism in the pathogenesis of GIT dysmotility mediated by functional anti-muscarinic receptor autoantibodies.
Conclusions
Despite extensive investigation, the pathogenesis of gastrointestinal involvement in systemic sclerosis remains elusive. Although treatment currently remains symptomatic, an improved understanding of novel pathogenic mechanisms may allow the development of potentially highly effective approaches including intravenous immunoglobulin and microRNA based therapeutic interventions.
INTRODUCTION
Systemic sclerosis (SSc) is a chronic systemic autoimmune disorder characterised by a severe and often progressive fibrotic process affecting the skin and numerous internal organs. Tissue fibrosis in SSc is accompanied by fibro-proliferative alterations in the microvasculature and various humoral and cellular immunological alterations leading to production of autoantibodies, tissue infiltration with chronic inflammatory cells and abnormalities in innate immunity. 1 Gastrointestinal tract (GIT) involvement occurs in greater than 90% of SSc patients. 2 Any part of the GIT from the mouth to the anus can be involved with dysmotility being the cardinal pathological abnormality contributing to the majority of symptoms. 3 GIT involvement occurs in both the diffuse and limited cutaneous subsets of SSc. Patients may present with symptoms of SSc GIT involvement in the absence of cutaneous disease. There is substantial variability in extent of involvement, severity and disease course in SSc GIT involvement with symptoms that are frequently nonspecific and overlapping for a particular anatomical site. Although GIT involvement is present in the majority of SSc patients it has been described that up to 8% of SSc patients develop severe GIT symptoms. This subset of SSc patients display increased mortality with only 15% survival at 9 years. 4 Gastrointestinal (GI) symptoms have also been associated with a reduction in health-related quality of life and contribute to depression, sleep disturbances and pain in SSc patients. [5] [6] [7] These factors create a vicious circle and cause inability to carry out daily activities, work disability, and limited overall physical functioning. Despite their frequency and severity and largely owing to the heterogeneity of clinical manifestations of SSc and to the lack of appropriate animal models, knowledge of the pathophysiology of GIT dysfunction in SSc is limited. The purpose of this review is to critically examine the current literature and to shed novel insights into the pathogenesis of GIT involvement in SSc. In addition, we will discuss the cardinal clinical manifestations of this complex disease and will identify potential areas for the development of novel therapeutic interventions.
METHODS
We searched PubMed, MEDLINE, and Google Scholar for articles about Systemic Sclerosis published in English between 1 January 1990, and 1 December 2016. We used the search terms "systemic sclerosis", "gastrointestinal", "oesophagus", "stomach", "intestine", "rectum", "anus", "antibody", "vasculopathy", "immune" and "pathogenesis".
RESULTS

Pathogenesis of SSc
The exact mechanisms involved in SSc pathogenesis are not well understood. However, it is apparent that the clinical and pathologic manifestations of the disease are the result of three distinct processes: (i) Fibroproliferative vascular lesions of small arteries and arterioles, (ii) fibrosis of skin and various internal organs induced by the increased production of various pro-fibrotic growth factors such as transforming growth factor-b (TGF-b), connective tissue growth factor, and insulin-like growth factor and (iii) multiple alterations of innate, humoral and cellular immunity resulting in the accumulation of lymphocytes and macrophages in affected tissues and the production of numerous autoantibodies. [8] [9] [10] [11] [12] Although the putative aetiologic agent and the exact mechanisms involved have not been determined, recent studies have provided novel information about the early events in SSc pathogenesis. As a result of those studies, it has been postulated that there is a sequence of alterations initiated by unknown aetiologic factors in a genetically receptive host. The earliest events induce structural and functional endothelial cell abnormalities affecting selectively the microvasculature. 13, 14 These alterations cause increased production and release of numerous cytokines, chemokines and polypeptide growth factors that result in the recruitment of bone marrow-derived and circulating fibrocytes and in the phenotypic conversion of quiescent tissue fibroblasts, and of epithelial and endothelial cells into activated myofibroblasts, the cells ultimately responsible for the fibroproliferative vasculopathy and progressive tissue fibrosis. 13, 15, 16 These alterations also result in chemokine and cytokine-mediated attraction of specific inflammatory cellular elements from the bloodstream and bone marrow to the affected tissues and in the activation of resident tissue macrophages resulting in the establishment of a chronic inflammatory process. 17, 18 This sequence of events is diagrammatically illustrated in Figure 1 .
Pathogenesis of GIT involvement in SSc
The pathogenesis of GIT SSc is complex and poorly understood. There is a paucity of studies examining the aetiology and pathogenesis of GI manifestations in SSc.
Smoking is the only environmental toxin that has been linked to increased severity of GIT symptoms in patients with SSc. 19 Evidence that a strong genetic component is linked to GIT SSc is highlighted by a study demonstrating that Canadian North American Native patients had more severe GIT involvement compared to Caucasian Americans. 20 Studies have also demonstrated a high prevalence of Helicobacter pylori infection in SSc patients, supporting a role for an infectious aetiology. 21 Fibroproliferative vasculopathy, immune dysfunction and fibrosis have been postulated as pathogenic mechanisms of GIT dysfunction and structural alterations in SSc (Figure 1 ). In the following sections, we highlight the important role of each of these pathogenic processes in relation to the GIT involvement in SSc. Furthermore, we discuss the results of recent studies that have identified and explored unique and novel mechanistic pathways and have allowed to postulate a novel pathogenic model for GIT involvement in SSc.
Vasculopathy. Endothelial cell injury has been recently suggested to play a crucial role in SSc pathogenesis and results in increased production of reactive oxygen species and release of chemokines and growth factors, which lead to recruitment of inflammatory T and B cells and pro-fibrotic macrophages in the interstitium of affected tissues. Activated inflammatory cells and tissue hypoxia resulting from structural vascular damage cause further release of reactive oxygen species, cytokines and profibrogenic mediators that propel the disease process.
1 Studies in GIT SSc have shown evidence of diminished mucosal blood flow in the duodenum and gastric antrum. 22 Histological studies of the oesophagus and stomach have demonstrated endothelial cell apoptosis, perivascular infiltrates and basement membrane thickening. 23, 24 Vascular lesions such as gastric antral vascular ectasia (GAVE) and telangiectasia of the digestive tract are representative of the diffuse vasculopathy affecting the GIT as illustrated in Figure 2 . 25, 26 Humoral immunity. Although the presence of numerous autoantibodies is one of the critical manifestations of SSc, the occurrence of functional autoantibodies capable of causing significant dysfunction of mouse colonic smooth muscle contraction by M 3 -R inhibition was not described until quite recently when Goldblatt et al. demonstrated the presence of such autoantibodies in the serum of SSc patients. 27 Subsequent studies revealed that immunoglobulins isolated from the serum of SSc patients (SScIgGs) interfere with neurally (cholinergic)-mediated contraction of the GIT. This was evidenced by the demonstration that SScIgGs caused specific attenuation of the simultaneous rat colonic contractile response and release of acetylcholine induced by electric field stimulation. SScIgGs were also found to abrogate the M 3 -R agonist-induced contractile response of rat colonic smooth muscle in a dose-dependent manner. 28, 29 Most recently, it was shown that SScIgGs lead to GI cholinergic dysfunction by binding at the M 3 -R on the GI smooth muscle and the myenteric cholinergic neurons of the rat colon ( Figure 3 ). Further analysis revealed that IgG's isolated from SSc patients early in their disease course bind with greater intensity to the myenteric neurons. As the disease duration increases, there is progressive increase in binding at both the smooth muscle and myenteric neurons. Of substantial therapeutic significance were the observations that the neural and myogenic effects of the SScIgGs were abrogated by the administration of pooled human intravenous immunoglobulin (IVIG) and its antigen binding fragment F(ab 0 ) 2 .
30
Cell-mediated immunity. Numerous studies have demonstrated strong evidence for the role of cellmediated immunity (CMI) in SSc. [31] [32] [33] Recent studies have shown that alterations in CMI are important participants in GIT involvement in SSc. Gastric biopsy specimens have demonstrated accumulation of immune cell infiltrates mainly consisting of CD4+ T lymphocytes with a pronounced increase in the CD4+/CD8+ T cell ratio. 34 SSc in general has a predominant Type 2 helper (Th2) polarisation of CD4+ T cells. 1 IL-4 causes na€ ıve CD4+ cells to differentiate into Th2 cells by downstream activation of STAT6 and GATA3, which lead to further production of IL-4 and IL-13, the classic Th2 cytokines. 35 IL-4 in a positive feedback amplifies its own response and also up-regulates humoral immunity by inducing immunoglobulin production and isotype switching ( Figure 1 ). IL-13 along with IL-6 released from various cells are pro-fibrotic cytokines that cause fibrosis by direct pro-fibrotic effects as well as by activating TGF-b. 33 The presence of increased CD4+ cells in gastric biopsy specimens could be responsible for excessive production of pathogenic autoantibodies and the extensive GIT fibrosis, as described above.
Fibrosis. Fibrosis disrupts the normal tissue architecture and leads to a nonfunctioning GIT. TGF-b produced by activated fibroblasts and immune cells leads to extensive fibrosis by Smad-dependent and Smad-independent pathways, 36 and in conjunction with endothelin-1 (derived from endothelial cells) participates in the conversion of fibroblasts into myofibroblasts. 11, 16 Myofibroblasts produce excessive fibrillar type l and type lll collagen along with other extracellular matrix components, initiate expression of a-smooth muscle actin and are the cells ultimately responsible for the fibrotic process. 9, 37-39 Gastric wall biopsies of SSc patients show generalised patchy fibrosis, increase deposition of type l and type lll collagen in the muscularis mucosae, submucosa and muscularis propria, and strong expression of fibrogenic cytokines including TGF-b, connective tissue growth factor and the myofibroblast marker a-smooth muscle actin ( Figure 4 ). 40 As collagen has a higher elastic modulus than smooth muscle, its deposition in the intestinal wall leads to increased stiffness, subsequently causing impaired muscle contractility. Furthermore, increased tissue stiffness has been recently shown to represent a potent stimulus for further fibrotic deposition. 41, 42 Besides fibroblasts, telocytes (peculiar type of stromal cells with long cytoplasmic processes) essential for extracellular matrix scaffolding are damaged and severely reduced in fibrotic areas of gastric muscle in SSc. 43 Recent studies have also highlighted the role microRNA (miRNA) in SSc pathogenesis. Differentially expressed miRNAs that target both inflammation and fibrosis have been identified in SSc. 44, 45 These miRNAs may be either anti-or pro-fibrotic. Of these miRNAs, the ones that modulate TGF-b signalling and the expression of related genes encoding collagens, metallopeptidases, and integrins are the most significant. The miR-29 family has been extensively studied in relation to SSc. 46 Indeed, miR-29, which targets collagen gene expression and regulates fibrosis, has been shown to be severely reduced in SSc skin biopsies 47 and reduced levels of miR-29 have been suggested to lead to increased tissue deposition of collagen.
Proposed pathogenesis of SSc GIT involvement
We recently proposed that GIT dysfunction in SSc is a staged process beginning with neuropathy and progressing to myopathy, with eventual fibrosis. 30 The initial neuropathic damage leads to disrupted contraction in response to neural stimulation, which is followed by a substantial reduction in amplitude of contractions signifying the development of myopathy. 30 The earliest evidence for neuropathy was obtained in a study that showed contractile response of the oesophageal smooth muscle of SSc patients to the direct acting muscarinic agonist methacholine but not to edrophonium, which acts indirectly. 26 These and numerous subsequent studies suggested that in the early stages of SSc GIT involvement circulating M 3 -R autoantibodies block cholinergic neurotransmission by inhibition of acetylcholine release at the myenteric cholinergic nerves (neuropathic damage), and that progression of the disease leads to myopathy via inhibition of acetylcholine action at the GI smooth muscle cell. 30 Some of these studies further suggested a temporal increase in binding of SScIgGs to the neural and myogenic M 3 -R with disease duration, observations that may account for the progressive nature of GIT involvement in SSc. The demonstration of autoantibody- mediated inhibition of neurotransmission provides a cogent rationale to the well-demonstrated observations that SSc patients may develop GIT manometric abnormalities long before the occurrence of histological changes in the GIT. As acetylcholine is the principal excitatory neurotransmitter in the GIT, inhibition of its release results in the absence of response of the smooth muscle in the GIT and its inability to contract in response to physiological stimuli. However, intestinal dysfunction at this stage is still reversible if the M 3 -R autoantibodies can be removed from the plasma or neutralised. Subsequently, loss of GIT contractile function may be the result of disuse muscle atrophy and progressive SSc-related tissue fibrosis (Figure 4 ). Once fibrosis ensues the smooth muscle is unable to respond to any type of external stimuli and treatment of dysmotility at this stage is ineffective. The fibrosed and dysfunctional GIT leads to reflux of gastric acid contents into the oesophagus, a dilated and noncompliant stomach, overgrowth of bacteria in the small intestine, colonic dilatation and a nonfunctional internal anal sphincter, alterations that manifest clinically as Barrett's oesophagus, gastroparesis, severe malabsorption and faecal incontinence respectively. Increased accumulation of fibrillary collagens and reduced expression of matrix metalloproteinase-1 along with GIT dysmotility lead to development to wide mouth diverticula, which have been reported in the oesophagus, small intestine and the colon. 48 The pathogenesis of GAVE and vascular ectasia in the small intestine has been suggested to be analogous to the vasculopathy responsible for the cutaneous and other vascular manifestations of SSc ( Figure 2 ).
Clinical manifestations
Oral cavity. There are numerous oral cavity alterations related to SSc involvement. 49 Fibrosis and tethering of the perioral skin leads to decreased oral aperture. Approximately 20% of patients develop secondary Sj€ ogren's syndrome leading to difficulty in mastication and poor dental hygiene. Typical oral cavity manifestations of SSc are the thickening of the sublingual frenulum and the widening of the periodontal ligament that may result in tooth loosening or tooth loss. 50, 51 A total of 10-20% of patients develop mandibular resorption, which can pre-dispose to pathological fractures, osteomyelitis and trigeminal neuralgia. 52 An increased incidence of tongue cancer has also been reported in patients with the diffuse subset of SSc. 53 Oropharyngeal dysphagia has been reported in up to 25% of patients and may occur as a reflex mechanism in patients with gastroesophageal reflux (GERD) or be secondary to thickening of the muscles of the lower pharynx and upper oesophagus. 54 All these factors together pre-dispose to decreased oral intake, malnutrition and subsequent weight loss.
Oesophagus. The oesophagus is the most common GI organ affected and oesophageal involvement occurs in 75-90% of SSc patients. 55 Symptoms include dysphagia, odynophagia, heartburn and regurgitation but patients can also present with other symptoms related to oesophageal reflux such as chronic cough, hoarseness, pharyngitis, laryngospasm or asthma. Although oesophageal involvement is present in both limited and diffuse SSc, a recent study concluded that oesophageal dysmotility is more common in patients with diffuse SSc and is more likely to deteriorate over time compared to patients with limited SSc. 56 Another study that assessed oesophageal motor function by high-resolution manometry found that severe oesophageal dysmotility is associated with longer duration of SSc and with the presence of interstitial lung disease. 57 Characteristically, there is decreased or absent primary peristalsis in the lower twothirds of the oesophagus with reduction in lower esophageal sphincter (LES) tone leading to a dilated and patulous oesophagus (Figure 5a ). These two factors predispose to GERD, which can be further exacerbated by gastroparesis. GERD is also associated with higher prevalence and rapid progression of interstitial lung disease, most likely caused by repeated micro-aspiration of gastric contents into the lungs. 58, 59 Frequently, patients with long-standing GERD progress to develop severe reflux oesophagitis even associated with peptic strictures (Figure 6a ) and Barrett's oesophagus (Figure 6b ) with its potential for development of oesophageal adenocarcinoma. The prevalence of Barrett's oesophagus in SSc is estimated to be 12%, which is essentially similar to that in patients with GERD without SSc. However, a recent study has reported an increased risk of oesophageal adenocarcinoma in a European cohort of SSc patients with Barrett's oesophagus. 60 Pill-induced dysphagia secondary to reduced clearance of oesophageal contents or candida oesophagitis due to effect of immunosuppressive medication are other common causes of dysphagia in SSc patients that require prompt diagnosis. Although SSc oesophageal involvement is one of the most common manifestations of SSc GIT, it should be emphasised that up to 30% of SSc patients may have asymptomatic oesophageal involvement. 61 Stomach. Gastric involvement in SSc leads to gastroparesis and GAVE. 62 Symptoms range from early satiety, vomiting, epigastric discomfort and bloating to complete intolerance of food contributing to severe weight loss and malnutrition. Symptoms of vomiting, epigastric discomfort and post-prandial bloating may indicate delayed gastric emptying. Gastroparesis aggravates GERD as evidenced by studies demonstrating severe oesophageal mucosal abnormalities in patients who have gastroparesis. 63 Decreased frequency and low amplitude of migrating motor complex (MMC) is seen in phase I/II in the fasting state and phase III in the post-prandial state.
Patients with SSc are pre-disposed to develop GAVE 62 ( Figure 6c ). The pathophysiology of GAVE in SSc has been suggested to be secondary to immune-mediated vasculopathy similar to that responsible for the development of telangiectasias and Raynaud's phenomenon. 64 The prevalence of GAVE in SSc is estimated to be 5.7-22.3%. 25, 64, 65 Usually, GAVE occurs within the first few years of SSc onset. 66 However, in a subset of patients GAVE could be the first manifestation of SSc occurring even in the absence of any other cutaneous features. It can present as asymptomatic iron deficiency anaemia, occult GI bleeding, melena or haematemesis. Previous studies have associated GAVE with the presence of anti-RNA pol III autoantibodies and the absence of antitopoisomerase I antibodies. 66 Recent studies confirmed the negative association with anti-topoisomerase I antibodies, but did not find any association with anti-RNA pol III autoantibodies. 25, 64 Further studies will be needed to confirm these findings and to render them clinically useful.
Small bowel. The small intestine is the second most common GIT organ involved in SSc. The main clinical entities associated with small bowel involvement are chronic intestinal pseudo-obstruction (CIPO), pneumatosis cystoides intestinalis (PCI), small intestinal bacterial overgrowth (SIBO) and jejunal diverticula. The small intestine in SSc patients is dilated, and displays increased stiffness and decreased muscle contractility. 67 Small intestine manometry shows abnormalities or absence of phase III MMC and post-cibal small-bowel hypomotility. 68 Patients have a wide variety of symptoms including nausea, vomiting, bloating, abdominal distension/pain, diarrhoea or systemic symptoms secondary to malabsorption. Pseudo-obstruction in SSc may be acute or chronic. 69 Dilatation, atony and delayed transit of the small intestine pre-dispose to pseudo-obstruction. Concomitant use of opiates in SSc has an additive effect on delaying intestinal transit. Intestinal stasis due to dysmotility predisposes to SIBO that is present in up to 50% of SSc patients. 70 Patients present with steatorrhea, weight loss and vitamin and nutritional deficiencies. Studies have demonstrated that SIBO contributes substantially to intestinal symptoms and correlates with a high global digestive symptom score. 70 , 71 PCI is a rare radiographic diagnosis characterised by radiolucent cysts within the wall of the small intestine caused by the presence of air in the submucosa or subserosa. 72 Impaired intestinal motility leading to bacterial overgrowth, ischaemic damage and mucosal atrophy are thought to contribute to its pathogenesis. Usually asymptomatic, these cysts can rupture occasionally and cause benign spontaneous pneumo-peritoneum. As its name implies, this condition is benign and should be treated conservatively with oxygen, antibiotics and bowel rest. Jejunal diverticula are true diverticula that develop due to protrusion of the intestinal wall at points of muscle atrophy. Although asymptomatic, they can sometimes perforate or lead to bacterial overgrowth.
Malnutrition. The prevalence of malnutrition in SSc is reported to be 18-56% in different studies. 73, 74 Although GIT pathology undoubtedly contributes to malnutrition, cachexia from chronic inflammation is the key mechanism for malnutrition in SSc patients as evident by studies demonstrating an association between poor nutritional status and overall disease activity and severity. 74 Presence of malnutrition is a predictor of shortened life survival with up to 4% deaths in SSc attributed to it. 73 As per the American Society of Parenteral and Enteral Nutrition, patients should be screened for malnutrition when the SSc diagnosis has been established and then annually, and those recognised at risk should be closely monitored and treated promptly. 75 Parenteral nutrition is often the last resort in patients with severe malnutrition. A trial of naso-enteral feeding should be undertaken to determine tolerability and benefit before a percutaneous endoscopic gastrostomy is performed. Percutaneous endoscopic jejunostomy, which has the added benefit of reducing pulmonary aspiration risk, should be considered in patients with severe gastroparesis. In patients who cannot tolerate this procedure or in those who have severe intestinal involvement, long-term home parenteral nutrition should be instituted.
Colon. Dysmotility, telangiectasia and diverticula are the hallmarks of colonic involvement in SSc. Although colonic involvement is often asymptomatic, it can clinically manifest with abdominal distension, diarrhoea or chronic constipation. Initially, dysmotility leads to constipation that can be severe enough to cause faecal impaction or even perforation of the large bowel requiring surgical treatment. In advanced cases, the colon is dilated with loss of haustrations. Diverticula are characteristically described as 'wide mouth' as illustrated in Figure 5c and generally are asymptomatic and not prone to diverticulitis.
Anus. Anorectal involvement is present in 50-70% of SSc patients. 76 Patient's symptoms include faecal impaction, constipation, faecal incontinence, tenesmus or painful defecation. Faecal incontinence affects up to 40% of patients in SSc and may be due to constipation with overflow, rectal prolapse, internal anal sphincter dysfunction or reduced rectal compliance and capacity. In addition, diarrhoea resulting from small or large bowel dysmotility and malabsorption can contribute to faecal incontinence. 77 The internal anal sphincter smooth muscle is the main determinant of basal tone and contributes to 80% of the resting anal pressure. Internal anal sphincter dysfunction secondary to neuropathy or myopathy is thought to be the primary cause of faecal incontinence. 78, 79 The majority of patients have a thinned and hyperechoic internal anal sphincter from SSc-related vasculopathy causing tissue atrophy but a sub-group of patients may have a thick and hypoechoic pattern secondary to tissue fibrosis and excessive collagen deposition. 80 Anal involvement in SSc is associated with reduced anal sphincter resting pressure and compliance with impaired rectoanal inhibitory reflex 81 and normal squeeze pressures. Similar to the manometric alterations in the oesophagus, manometric anorectal abnormalities in SSc may appear much before clinical symptoms develop.
78, 79
Liver. Primary biliary cholangitis (PBC) is the liver disorder most consistently reported in patients with SSc. Its onset may precede or follow the diagnosis of SSc. The association of PBC with Raynaud phenomenon is known as Reynolds syndrome. 82, 83 Compared to a prevalence of 0.04% in the general population, the prevalence of PBC has been reported to be 2-22% in patients with SSc. 84, 85 PBC is commonly associated with the limited subset of SSc and anti-centromere antibody positivity. However, up to 20% of SSc patients may harbor PBC screen antibodies (anti-mitochondrial, gp21 and sp100 antibodies) in the absence of liver disease. 86 For unknown reasons, PBC associated with SSc has a slower progression to end stage liver disease and lower rate of liver transplantation compared to patients with PBC alone. 87 Nodular regenerative hyperplasia (NRH), a rare cause of noncirrhotic intrahepatic portal hypertension, has been increasingly recognised in association with both limited and diffuse SSc. 88, 89 Several facts support this observation. The pathogenesis of NRH, characterised by obliterative changes in portal veins is similar to the microvascular damage present in SSc. 90 NRH has also been associated with toxic oil syndrome an entity similar to SSc. 91 Moreover, a study of 35 liver biopsies of 30 patients with early PBC showed nodular hyperplastic changes in 47% of specimens. 92 Whether the association of NRH to SSc is an effect modification due to PBC or an epiphenomenon will have to be studied further. The majority of patients with NRH are asymptomatic and therefore a high index of suspicion in the SSc population is essential to identify patients who may develop portal hypertension. 90 Autoimmune hepatitis, 93 idiopathic portal hypertension, and primary sclerosing cholangitis are the other liver diseases that have been reported in patients with SSc. Owing to the autoimmune nature of SSc, some patients may harbor anti-liver kidney microsomal antibodies (anti-LKM) or anti-smooth muscle antibodies (anti-SMA) in the absence of liver disease. 94 Pancreas. Clinical evidence of pancreatic involvement in SSc is rare. However, although usually attributed to SIBO, malabsorption in SSc can also be caused by exocrine pancreatic insufficiency. 95 Case reports of fatal pancreatic infarction and acute haemorrhagic pancreatitis secondary to occlusion of medium-sized pancreatic arteries in SSc, have been described as well.
96
SSc GIT involvement: outcome measurements The construction of validated questionnaires that correlate patient symptoms to objective assessment of disease has been a major development in the last decade. The initial GIT-targeted health-related quality of life instrument known as Scleroderma Gastrointestinal Tract 1.0 (SSC-GIT 1.0) instrument 97 was revised in 2009 to a much shorter 34-item instrument that was termed 'University of California, Los Angeles Scleroderma Clinical Trial Consortium GIT 2.0 (UCLA SCTC GIT 2.0)'. 98 The UCLA SCTC GIT 2.0 instrument retained 33 items from the SSC-GIT 1.0 and added 1 item for faecal soilage (to assess rectal incontinence), and split the reflux/ indigestion scale into reflux and distention/bloating. Each item in this scale is scored on a 0-3 range, with lower values indicating better health related quality of life. This scale has the added advantage of calculating the total GIT score, which correlates with the overall burden of GI disease in SSc patients.
Recently an initiative by the National Institutes of Health has lead to the development of the PatientReported Outcomes Measurement Information System (PROMIS) GI symptom item bank containing 60 items that capture 8 GI-specific symptom scales. 99 Compared to GIT 2.0, the PROMIS GI bank has additional scales for disrupted swallowing and nausea/vomiting. A recent study comparing PROMIS to the legacy instrument GIT 2.0 in SSc revealed large correlation and demonstrated satisfactory reliability amongst the two scales. 100 PROMIS instruments have an added advantage of reduction in respondent burden, easy comprehensibility and usability across diverse populations.
SSc GIT involvement: diagnosis and treatment
Diagnosis and management of GIT disease requires a collaborative and multidisciplinary approach. 101 Once a rheumatologist confirms the diagnosis of SSc, the patient should be referred to a gastroenterologist even in the absence of GI symptoms. 102 Consultation with an oral surgeon should be obtained as well. Patients with GI symptoms should undergo annual screening to detect malnutrition. Typical radiological, serological, endoscopic and manometric findings assist in establishing a diagnosis and detecting complications (Tables 1 and 2 ). Adverse effects related to long-term use of proton pump inhibitors should be closely monitored. The role of social and psychological factors should not be ignored, as they might be the cause rather than effect of some of the symptoms. Treatment of GIT manifestations in SSc is symptomatic and consists of acid reducing therapy, intermittent or cyclic administration of antibiotics of different classes and use of pro-kinetic agents (Table 3) . Currently, there are no disease modifying drugs for this devastating complication of SSc as limited knowledge about pathogenesis and lack of appropriate animal models of GIT SSc has hampered development of new therapies. Early diagnosis and identification of patients at high risk is crucial, as once fibrosis ensues, dysmotility might become irreversible. Immunosuppressive drugs that target profibrotic cytokines and IVIG offer hope for treatment of GIT involvement in SSc. IVIG could potentially have multiple beneficial effects in SSc not only by anti-idiotypic mediated neutralisation of muscarinic autoantibodies but also by causing reduction in pro-fibrotic cytokines or by counteracting the deleterious effects of anti-fibroblast or anti-endothelial cell circulating antibodies. IVIG is relatively safe compared to immunosuppression and has been shown to be beneficial in halting progression of GI symptoms in observational studies and to reverse cholinergic dysfunction induced by M 3 -R autoantibodies in vivo. 29, 30, [103] [104] [105] Targeting miR-29 by anti-miRs, which are chemically modified oligonucleotides, is another promising therapeutic option in the future. 46, 106 However, rigorous studies are needed before patients can be benefited from these novel interventions. 
CONCLUSION
Gastrointestinal tract involvement is the most common noncutaneous organ system involved in SSc and is associated with substantial morbidity and mortality. Our current understanding of the pathogenesis and treatment of this entity is still far from complete, owing to the limited number of studies that have focused on histopathological, cellular and molecular changes in the GIT. Autoantibody-mediated dysmotility offers a new avenue for further research into the pathogenesis and treatment of GI SSc. Moreover, there is lack of non-invasive tests or biomarkers, which can identify patients who are at high risk for development of GIT manifestations. Early identification and symptomatic treatment of patients is crucial until more targeted and effective disease-modifying therapeutic approaches become available. Improved understanding of the pathogenesis of GIT manifestations of SSc employing focused and intensive cellular and molecular studies, research endeavours aimed at identification of novel disease biomarkers, and extensive efforts to develop personalised medical therapies should allow achieving these goals in the near future.
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